RMD
Price
$228.93
Change
-$8.34 (-3.51%)
Updated
Dec 23, 10:36 AM (EDT)
31 days until earnings call
SRDX
Price
$39.75
Change
-$0.16 (-0.40%)
Updated
Dec 20 closing price
38 days until earnings call
Ad is loading...

RMD vs SRDX

Header iconRMD vs SRDX Comparison
Open Charts RMD vs SRDXBanner chart's image
ResMed
Price$228.93
Change-$8.34 (-3.51%)
Volume$1.76K
CapitalizationN/A
Surmodics
Price$39.75
Change-$0.16 (-0.40%)
Volume$309.79K
CapitalizationN/A
RMD vs SRDX Comparison Chart
Loading...
RMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RMD vs. SRDX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RMD is a Hold and SRDX is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (RMD: $237.27 vs. SRDX: $39.75)
Brand notoriety: RMD and SRDX are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: RMD: 320% vs. SRDX: 152%
Market capitalization -- RMD: $29.13B vs. SRDX: $397.04M
RMD [@Medical Specialties] is valued at $29.13B. SRDX’s [@Medical Specialties] market capitalization is $397.04M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RMD’s FA Score shows that 1 FA rating(s) are green whileSRDX’s FA Score has 0 green FA rating(s).

  • RMD’s FA Score: 1 green, 4 red.
  • SRDX’s FA Score: 0 green, 5 red.
According to our system of comparison, RMD is a better buy in the long-term than SRDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RMD’s TA Score shows that 3 TA indicator(s) are bullish while SRDX’s TA Score has 4 bullish TA indicator(s).

  • RMD’s TA Score: 3 bullish, 6 bearish.
  • SRDX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, SRDX is a better buy in the short-term than RMD.

Price Growth

RMD (@Medical Specialties) experienced а -0.52% price change this week, while SRDX (@Medical Specialties) price change was -0.70% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.07%. For the same industry, the average monthly price growth was -0.10%, and the average quarterly price growth was +2.22%.

Reported Earning Dates

RMD is expected to report earnings on Jan 23, 2025.

SRDX is expected to report earnings on Jan 30, 2025.

Industries' Descriptions

@Medical Specialties (-1.07% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RMD($29.1B) has a higher market cap than SRDX($397M). SRDX has higher P/E ratio than RMD: SRDX (71.51) vs RMD (31.34). RMD YTD gains are higher at: 39.219 vs. SRDX (9.354). RMD has higher annual earnings (EBITDA): 1.43B vs. SRDX (22.1M). RMD has more cash in the bank: 210M vs. SRDX (35.2M). SRDX has less debt than RMD: SRDX (33.9M) vs RMD (1.39B). RMD has higher revenues than SRDX: RMD (4.5B) vs SRDX (138M).
RMDSRDXRMD / SRDX
Capitalization29.1B397M7,330%
EBITDA1.43B22.1M6,471%
Gain YTD39.2199.354419%
P/E Ratio31.3471.5144%
Revenue4.5B138M3,264%
Total Cash210M35.2M597%
Total Debt1.39B33.9M4,103%
FUNDAMENTALS RATINGS
RMD vs SRDX: Fundamental Ratings
RMD
SRDX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
92
Overvalued
PROFIT vs RISK RATING
1..100
49100
SMR RATING
1..100
4192
PRICE GROWTH RATING
1..100
4753
P/E GROWTH RATING
1..100
5794
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RMD's Valuation (18) in the Medical Specialties industry is significantly better than the same rating for SRDX (92). This means that RMD’s stock grew significantly faster than SRDX’s over the last 12 months.

RMD's Profit vs Risk Rating (49) in the Medical Specialties industry is somewhat better than the same rating for SRDX (100). This means that RMD’s stock grew somewhat faster than SRDX’s over the last 12 months.

RMD's SMR Rating (41) in the Medical Specialties industry is somewhat better than the same rating for SRDX (92). This means that RMD’s stock grew somewhat faster than SRDX’s over the last 12 months.

RMD's Price Growth Rating (47) in the Medical Specialties industry is in the same range as SRDX (53). This means that RMD’s stock grew similarly to SRDX’s over the last 12 months.

RMD's P/E Growth Rating (57) in the Medical Specialties industry is somewhat better than the same rating for SRDX (94). This means that RMD’s stock grew somewhat faster than SRDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RMDSRDX
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
58%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
68%
Momentum
ODDS (%)
Bearish Trend 4 days ago
65%
Bearish Trend 4 days ago
68%
MACD
ODDS (%)
Bearish Trend 4 days ago
62%
Bearish Trend 4 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
56%
Bearish Trend 4 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
51%
Bullish Trend 4 days ago
71%
Advances
ODDS (%)
Bullish Trend 4 days ago
66%
Bullish Trend 15 days ago
71%
Declines
ODDS (%)
Bearish Trend 11 days ago
61%
Bearish Trend 6 days ago
69%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
64%
Bearish Trend 5 days ago
73%
Aroon
ODDS (%)
Bearish Trend 4 days ago
58%
Bullish Trend 4 days ago
69%
View a ticker or compare two or three
Ad is loading...
RMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMCJX8.880.13
+1.49%
Miller Income A
MRGHX50.820.57
+1.13%
MFS Core Equity R3
RYEAX211.912.08
+0.99%
Rydex Energy H
GATAX51.890.43
+0.84%
Gabelli Asset A
BPSIX25.920.15
+0.58%
Boston Partners Small Cap Value II I